Figure 4
Figure 4. The effects of intramuscular immunization against influenza, with the adjuvant MF59, on FVIII immunogenicity. Mice were immunized intramuscularly with a scaled standard human dose (4.8 μg/kg) within 24 hours of the first of 7 rhFVIII (6 IU, ∼240 IU/kg) infusions. Blood was collected by cardiac puncture 4 weeks later and plasma was isolated by centrifugation. (A) Incidence of FVIII-specific IgG. Total cohort sizes are indicated above each bar. (B) Incidence of inhibitors. (C) Comparison of influenza- and FVIII-specific IgG titers among FVIII responders. (D) Comparison of inhibitory activity among FVIII responders. (E) Anti-FVIII IgG subclasses IgG1 and IgG2a among FVIII responders. The horizontal lines and error bars represent the mean and SEM.

The effects of intramuscular immunization against influenza, with the adjuvant MF59, on FVIII immunogenicity. Mice were immunized intramuscularly with a scaled standard human dose (4.8 μg/kg) within 24 hours of the first of 7 rhFVIII (6 IU, ∼240 IU/kg) infusions. Blood was collected by cardiac puncture 4 weeks later and plasma was isolated by centrifugation. (A) Incidence of FVIII-specific IgG. Total cohort sizes are indicated above each bar. (B) Incidence of inhibitors. (C) Comparison of influenza- and FVIII-specific IgG titers among FVIII responders. (D) Comparison of inhibitory activity among FVIII responders. (E) Anti-FVIII IgG subclasses IgG1 and IgG2a among FVIII responders. The horizontal lines and error bars represent the mean and SEM.

Close Modal

or Create an Account

Close Modal
Close Modal